J. Harris

发表

Phase II Study of Gemcitabine in Combination with Docetaxel in Patients with Advanced Pancreatic Carcinoma (E1298)

J. Berlin, V. Avilés, K. Stuart, 2004, Oncology.

Phase II trial of oral rubitecan in previously treated pancreatic cancer patients.

H. Burris, K. Mettinger, H. Gerstein, 2005, The oncologist.

Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas

S. Shott, J. Plate, J. Harris, 2005, Cancer Immunology, Immunotherapy.

Adjuvant and neoadjuvant therapies of pancreatic cancer

H. Bruckner, J. Harris, 2001, International journal of gastrointestinal cancer.

The effect of immunosuppressive chemotherapy on immune function in patients with malignant disease

T. Stewart, J. Harris, Dharmendra S. Sengar, 1976, Cancer.

Suppression of the development of tumoricidal function in gamma interferon-treated human peripheral blood monocytes by lipopolysaccharide: The role of cyclooxygenase metabolites

L. Casey, D. Braun, J. Harris, 2004, Journal of Clinical Immunology.

ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.

Daniel F Hayes, R. Bast, M. Somerfield, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Augmentation of impaired tumoricidal function in alveolar macrophages from lung cancer patients by cocultivation with allogeneic, but not autologous lymphocytes

K. Siziopikou, L. Casey, D. Braun, 1997, Cancer Immunology, Immunotherapy.

Immunoregulation in pancreatic cancer patients

S. Shott, J. Plate, J. Harris, 1999, Cancer Immunology, Immunotherapy.

A Phase II Study of Gemcitabine and 5-Fluorouracil in Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study (E3296)

J. Berlin, S. Adak, D. Vaughn, 2000, Oncology.

Sensitivity of 1 umoricidal Function in Macrophages from Different Anatomical Sites of Cancer Patients to Modulation of Arachidonic Acid Metabolism 1

K. Siziopikou, G. Wilbanks, L. Casey, 2006 .

Caspase-Dependent and -Independent Panc-1 Cell Death Due to Actinomycin D and MK 886 are Additive but Increase Clonogenic Survival

W. Alrefai, P. Dudeja, T. Seed, 2003, Experimental biology and medicine.

The in vitro development of cytotoxicity in response to granulocyte/macrophage-colony-stimulating factor or interferon γ in the peripheral blood monocytes of patients with solid tumors: Modulation by arachidonic acid metabolic inhibitors

K. Siziopikou, L. Casey, D. Braun, 2005, Cancer Immunology, Immunotherapy.

Functional Assessment of Cancer Therapy

Charles R. Thomas, D. Tulsky, D. Cella, 2015 .

Prostaglandin Inhibitors in Tumor Immunology and Immunotherapy

D. Braun, K. Anderson, J. Harris, 1994 .

IMPAIRED IMMUNORESPONSIVENESS IN TUMOR PATIENTS *

J. Harris, D. Copeland, 1974, Annals of the New York Academy of Sciences.

Soluble membrane antigens of human malignant melanoma cells

R. Herberman, J. Minton, A. Hollinshead, 1974, Cancer.

The immunology of malignant disease

J. Sinkovics, J. Harris, 1976 .

Effect of L-Asparaginase on the Ability of Normal Mouse Bone Marrow to form Soft Agar Colonies

J. Harris, 1969, Nature.

5,8,11,14-Eicosatetraynoic acid-induced destruction of mitochondria in human prostate cells (PC-3)

T. Seed, K. Anderson, J. Harris, 1992, In Vitro Cellular & Developmental Biology - Animal.

Lymphokine‐activated killer cell induction in tumor‐infiltrating leukocytes from colon cancer patients

J. Harris, D. Braun, E. Staren, 1989, Cancer.

The Modulation of Fluorouracil With Leucovorin in Metastatic Colorectal Carcinoma A Prospective Randomized Phase III Trial

Michael R. Green, Jules E. Harris, J. Barkin, 1990 .

Modulation of tumoricidal function in alveolar macrophages from lung cancer patients by interleukin-6

Jules E. Harris, K. Siziopikou, L. Casey, 1997, Cancer Immunology, Immunotherapy.

Selected Features of Nonendocrine Pancreatic Cancer

K. Anderson, J. Harris, 2001, Experimental biology and medicine.

Serial immune function testing to predict clinical disease relapse in patients with solid tumors

D. Braun, J. Harris, 2004, Cancer Immunology, Immunotherapy.

Serial immune testing in surgically resected lung cancer patients

D. Braun, A. Hollinshead, J. Harris, 2004, Cancer Immunology, Immunotherapy.

IMMUNOCHEMOTHERAPY OF LUNG CANCER *

D. Klaassen, T. Stewart, R. Bélanger, 1976, Annals of the New York Academy of Sciences.

A phase II study of interleukin-2 with and without beta-interferon in the treatment of advanced renal cell carcinoma

M. Oken, M. Ernstoff, D. Trump, 2004, Investigational New Drugs.

Prostate Cancer Treatment Protocols

R. Ghavamian, G. Camporeale, J. Harris, 2014 .

Phase III study of combined chemohormonal therapy in metastatic prostate cancer (ECOG 3882)

P. Catalano, K. Propert, D. Trump, 2003, Medical oncology.

Comparison of 5‐fluorouracil alone, 5‐fluorouracil with levamisole, and 5‐fluorouracil with hepatic irradiation in the treatment of patients with residual, nonmeasurable, intra‐abdominal metastasis after undergoing resection for colorectal carcinoma

A. Cnaan, A. Schutt, E. Mansour, 2001, Cancer.

Renal medullary carcinoma: Clinical and therapeutic aspects of a newly described tumor

R. Weiss, R. Avery, C. Davis, 1996, Cancer.

Immunobiotherapy directed against mutated and aberrantly expressed gene products in pancreas cancer

J. Plate, J. Harris, 2005, Journal of cellular biochemistry.

Abnormal monocyte function in patients with Kaposi's sarcoma

D. Braun, J. Harris, 1986, Cancer.

Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and Bleomycin-CCNU in patients with advanced cancer of the anal canal: An eastern cooperative oncology group study E7282

P. Catalano, D. Haller, S. Mani, 2006, Investigational New Drugs.

Inhibition of U 937 Eicosanoid and DNA Synthesis by 5 , 8 , 11 , 14-Eicosatetraynoie Acid , an Inhibitor of Arachidonic Acid Metabolism and Its Partial Reversal by Leukotriene C 4

F. Ondrey, K. Anderson, J. Harris, 2006 .

MK 886 functions as a radiomimetic agent: genomic responses related to oxidative stress, the cell cycle, proliferation and programmed cell death in Panc-1 cells.

W. Alrefai, P. Bonomi, K. Anderson, 1999, Advances in Experimental Medicine and Biology.

Chemiluminescence, suppression and cytotoxicity in peripheral blood mononuclear cells from solid tumor cancer patients

D. Braun, J. Harris, K. D. Boer, 2004, Cancer Immunology, Immunotherapy.

Elevated serum heparanase‐1 levels in patients with pancreatic carcinoma are associated with poor survival

J. Platt, P. Gattuso, G. Brunn, 2006, Cancer.

Abnormal Immunoregulation in Human Cancer at the Actual Tumor Site

D. Braun, J. Harris, 1992 .

The effect of cytotoxic drugs on immunoregulatory cell function in solid tumor cancer patients

D. Braun, J. Harris, 1984 .

Effect of chemotherapy on NK function in the peripheral blood of cancer patients

D. Braun, J. Harris, 2004, Cancer Immunology, Immunotherapy.

Hepatitis and renal transplants.

J. Najarian, C. Ponticelli, C. Kjellstrand, 1977, The New England journal of medicine.

Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise.

M. Hanna, H. Pinedo, J. Vermorken, 2001, Vaccine.

Reactive oxygen species and redox-induced programmed cell death due to MK 886: cells ("soil") "trump" agent ("seed").

J. Harris, W. Alrefai, P. Dudeja, 2005, In vivo.

Hodgkin's disease: long-term effects of therapy.

K. Rowland, K. M. Rowland, A. Murthy, 1986, Medical and pediatric oncology.

Modulation of the immune response by chemotherapy.

J. E. Harris, D. Braun, J. Harris, 1981, Pharmacology & therapeutics.

Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients.

C. Shapiro, R. Gelman, D. Hayes, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283.

J. Manola, M. Hanna, M. Oken, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group.

D. Finkelstein, R. Hahn, D. Tormey, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Superficial bladder cancer.

M. King, J. Harris, M. King, 1985 .

Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: a prospective Eastern Cooperative Oncology Group study.

R. Gelman, J. Glick, C. Falkson, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial.

Samuel J. Taylor, J. Kirkwood, J. Harris, 1985, Cancer research.

Conventional dose melphalan is inactive in metastatic melanoma: results of an Eastern Cooperative Oncology Group Study (E1687).

M. Atkins, M. Strawderman, M. Oken, 1999, Anti-cancer drugs.

Ductal carcinoma in situ of the breast.

S. Bines, D. Bruetman, J. Harris, 1989, Medical and pediatric oncology.

Human PC‐3 prostate cell line DNA synthesis is suppressed by eicosatetraynoic acid, an in vitro inhibitor of arachidonic acid metabolism

J. Harris, F. Ondrey, K. Anderson, 1988, The Prostate.

Transformation of chronic lymphocytic leukemia to immunoblastic lymphoma (Richter's Syndrome)

W. Leslie, S. Gregory, H. Shahidi, 1997 .

Marimastat in patients with advanced pancreatic cancer: a dose-finding study.

E. Casper, A. Rosemurgy, J. Harris, 1999, American journal of clinical oncology.

5‐lipoxygenase inhibitors reduce PC‐3 cell proliferation and initiate nonnecrotic cell death

M. Vos, J. Harris, W. Alrefai, 1998, The Prostate.

Monocyte functional studies in asymptomatic, human immunodeficiency disease virus (HIV)-infected individuals

J. Harris, H. Kessler, A. Landay, 1988, Journal of Clinical Immunology.

Phase II Study of Cisplatin and 5-Fluorouracil (PF) and Mitomycin C, Vincristine, Cisplatin and 5-Fluorouracil (MVPF) in Patients with Metastatic Large Bowel Cancer: An Eastern Cooperative Oncology Group Study (EST 1285)

N. Petrelli, D. Haller, D. Vaughn, 2004, Oncology.